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Abstract Oligodendrogliomas may be divided into
those with deletion of chromosomes 1p and 19q
(Del+), and those without (Del¡). Del+ tumours show
better survival and chemoresponsiveness but the rea-
son for this diVerence is unknown. We have investi-
gated whether these subgroups diVer in (a) apoptotic
index, (b) the proportion of cells licensed for DNA
replication but not in-cycle, and (c) the relative length
of G1-phase. Fluorescence in situ hybridisation with
probes to 1p and 19q was used to determine the deletion
status of 54 oligodendrogliomas, including WHO
grades II and III. The apoptotic index was determined
using counts of apoptotic bodies. Replication-licensed
non-proliferating cells were determined from the
Mcm2 minus Ki67 labelling index, whilst the geminin
to Ki67 ratio was used as a measure of the relative
length of G1. Del+ oligodendrogliomas showed a
higher apoptotic index than Del¡ tumours (P =0 . 0 3 7 ) ;
this was not accounted for by diVerences in tumour
grade or in proliferation. There were no diVerences in
the Mcm2 ¡ Ki67 index or in the geminin/Ki67 ratio
between the subgroups, but grade III tumours showed
a higher proportion of licensed non-proliferating cells
than grade II tumours (P = 0.001). An increased sus-
ceptibility to apoptosis in oligodendrogliomas with
1p § 19q deletion may be important in their improved
clinical outcome compared to Del¡ tumours.
Keywords Oligodendroglioma · Apoptosis · 
Replication · DNA replication licensing · Cytogenetic
Introduction
Oligodendrogliomas are tumours composed of cells
that morphologically resemble oligodendrocytes and
that range in spectrum from well diVerentiated to ana-
plastic tumours. The current WHO classiWcation of
CNS tumours recognises two histological grades,
WHO grades II and III, and grading is a signiWcant pre-
dictor of survival [23]. Oligodendrogliomas have gen-
erally been considered to have a better prognosis than
the corresponding grades of diVuse astrocytoma, and
recent data continues to support this [21]. However,
oligodendrogliomas, like astrocytomas, are diVusely
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inWltrating tumours, precluding complete surgical
resection, and they may show malignant progression
over time. There is therefore a role for adjuvant radio-
therapy and/or chemotherapy, particularly for anaplas-
tic tumours.
Approximately two-thirds of oligodendrogliomas
show allelic losses from chromosomes 1p and 19q [24,
25], a genetic proWle that appears to be associated with
clinical outcome. Some anaplastic oligodendrogliomas
respond to combination chemotherapy [2, 3], and bet-
ter progression free survival and chemo-responsiveness
appear to be linked to the presence of these deletions
[4, 34]. Results from two recent large-scale trials pro-
vide support for the view that the presence of 1p 19q
deletion identiWes a subgroup with better clinical out-
come [1, 41]. 1p 19q deletion may also identify better
prognosis in low-grade oligodendrogliomas [13].
There may be some histopathological diVerences
between the two genetic subgroups. Classical oligoden-
droglioma features, such as perinuclear haloes (in
>50% of cells), uniform rounded nuclei, chickenwire
vascular pattern and calciWcation, are associated with
1p 19q loss [14, 27, 42], suggesting that classical fea-
tures, such as perinuclear haloes associated with
tumour cellularity, can predict genotype [14]. How-
ever, there are cases of histologically typical oligo-
dendrogliomas without 1p 19q deletion and more
astrocytic appearing tumours with deletion. For these
cases clinical behaviour appears to be better predicted
by genotype than phenotype, so that 1p 19q deletion
provides additional information to conventional histo-
pathological analysis [27]. Some studies suggest that
oligodendrogliomas with 1p 19q deletion have lower
activity of O6-methylguanine DNA methyltransferase
(MGMT) due to promoter hypermethylation and
decreased expression. MGMT is a DNA repair enzyme
associated with resistance to alkylating agents, so this
may contribute to chemosensitivity [18], although
other studies have not found a clear association [42].
At present, therefore, the biological basis for the
intrinsically better prognosis of the 1p 19q deletion
subgroup and the possible basis of a diVerent inter-
action with adjuvant therapies remain poorly under-
stood.
In this study we hypothesise that the diVerence in
behaviour of tumours with and without these deletions
is due to diVerences in kinetic properties of the
tumours related to proliferation and apoptosis. Apop-
totic bodies are often a conspicuous feature in oligo-
dendrogliomas and levels of apoptosis increase with
grade [43]. Tumour growth depends on the net eVects
of cell proliferation and loss [35] so that a subgroup of
tumours with a greater propensity to apoptosis versus
proliferation may have slower growth. It is thus possi-
ble that increased susceptibility of tumour cells to
undergo apoptosis might underlie both a better intrin-
sic biological behaviour and a greater sensitivity to
adjuvant therapy. We hypothesise therefore that tum-
ours with 1p,19q deletions show a greater tendency to
apoptosis that is reXected in increased basal levels of
apoptosis in the tumours.
DiVerences in kinetic parameters related to DNA
replication licensing are also candidates for relevance
to growth capacity and chemosensitivity. The initiation
of chromosomal replication is a crucial decision point
in cell proliferation that lies at the point of conver-
gence of all oncogenic signalling and transduction
pathways that trigger proliferation. DNA replication
initiation is precisely controlled through a core set of
licensing factors (Orc1–6, Cdc6, Cdt1, Mcm2–7) that
sequentially assemble into pre-replicative complexes
(pre-RCs) at »30,000 replication origins scattered
along the chromosomes, resulting in chromatin being
‘licensed’ for replication in the subsequent S phase.
Licensed replication origins are activated by the con-
certed action of S phase promoting kinases (Cdk2) and
the ASK-dependent Cdc7 kinase in a process com-
monly known as ‘origin Wring’. Origin Wring results in
local melting of the DNA helix at replication origins
and the recruitment of DNA polymerases (reviewed in
[40]). Notably the Mcm2–7 replication licensing fac-
tors, which have been shown to act as a replicative
DNA helicase, are present within the nucleus in cells
in-cycle, but are down-regulated in out-of-cycle states
[10, 38].
We have previously shown that higher grade oligo-
dendrogliomas show a greater proportion of cells that
are licensed for DNA replication, as determined by the
Mcm2 labelling index, which is of prognostic signiW-
cance [44]. Certain tissues contain a population of
licensed but non-proliferating cells [10, 38] and higher
labelling indices for Mcm2 than for the conventional
proliferation marker Ki67 (which marks all four phases
of the cell-cycle) suggest that this may be true for oligo-
dendrogliomas [44]. A population of licensed but non-
proliferating cells might conceivably resist cell-cycle
dependent cytotoxicity and form a viable cell cache
for tumour re-population. We have used the diVerence
between the Mcm2 and Ki67 labelling indices
(Mcm2 ¡ Ki67 LI) as an assay of this population.
It is essential for faithful propagation of the genome
that origins are Wred once and only once in each cell
cycle to avoid re-replication events, which would lead
to gene ampliWcation. Geminin, a 23.5 kDa nuclear
protein, is an endogenous regulator of chromosomal
replication, absent during G1 phase but allowed toActa Neuropathol (2007) 113:119–127 121
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accumulate during S, G2 and M phase [17]. Geminin
acts to prevent a second, inappropriate Wring of repli-
cation origins by competitively binding to Cdt1 and
thereby blocking recruitment of the Mcm2–7 helicase
to replication origins [39, 48]. Thus pre-RC re-assem-
bly and Wring are prevented. At the metaphase to ana-
phase transition in mitosis, the anaphase promoting
complex (APC/C) becomes activated and geminin is
targeted for polyubiquitination and degradation via the
26S proteosome pathway, lowering levels to the point
where the protein no longer interferes with assembly of
pre-RCs during the following G1 phase [17]. Since
geminin is present in S–G2–M phase, the ratio of gemi-
nin to Ki67 may provide an index of the relative length
of G1-phase. We have previously shown that this ratio
decreases in higher-grade oligodendrogliomas, which
may be a reXection of a shortened G1 in anaplastic
tumours [45]. The length of G1-phase may be relevant
to chemotherapeutic agents targeting the cell cycle
machinery. We have therefore determined whether
cytogenetic subgroups of oligodendrogliomas diVer in
their geminin/Ki67 ratio.
Materials and methods
A total of 55 cases of oligodendroglioma were identi-
Wed and paraYn blocks retrieved from the archives of
the Histopathology Department of the Royal Hallam-
shire Hospital, SheYeld, from a 12 year period from
1985 to 1997. As previously described [45], 25 cases
were graded as WHO grade II (mean age 37.4 years)
and 30 as grade III (mean age 44.6 years). The series
comprised 22 female and 33 male patients. All of the
cases were resection specimens; stereotactic and other
small biopsies were excluded. Of these cases, 47 were
Wrst resections. Eight cases were recurrent resections
that fell within the study period; the initial resections
on these cases were prior to the study period and not
included. All of the cases were used for the labelling
index analyses but only the 47 Wrst resections were
used for survival analysis. Clinical follow-up data and
data on radiotherapy and chemotherapy were
obtained from the Clinical Oncology Department at
Western Park Hospital, SheYeld. Approval for the
study was granted by the Local Research Ethics
Committee.
Immunohistochemistry
Immunohistochemistry was performed on serial sec-
tions from a representative paraYn block from each
case using a standard ABC method and the signal
visualised using diaminobenzidine. Immunostaining
was performed to Ki67 (Novocastra), Mcm2 (BD
Transduction Laboratories) and geminin (G95, rabbit
polyclonal) on this series of tumours as previously
described [45]. Apoptotic bodies were counted on hae-
matoxylin and eosin stained sections. Areas of highest
cellularity were used for quantitation. The percentage
of labelled cells, derived from a count of at least 1000
cells, was determined for each marker using an eye-
piece graticule [44, 45].
Fluorescence in situ hybridisation
Fluorescence in situ hybridisation (FISH) was per-
formed on 4  thick sections using the technique previ-
ously described [7]. The Vysis dual colour probe sets
LSI 1p36/LSI 1q25 and LSI 19p13/LSI 19q13 were used
according manufacturers instructions; probes were
hybridised overnight using a PTC Peltier Thermal
Cycler. Analysis was performed independently by two
scientists, both scoring 30 cells for each probe set.
Statistical analyses
Statistical analyses were performed using the statistical
package for the social sciences (SPSS v10.1). Comparison
of age was made using an unpaired t test. Data on label-
ling indices was either not normally distributed and/or
did not satisfy criteria for equality of variance between
groups (Levene’s test). Therefore comparisons of label-
ling indices between groups were performed using the
non-parametric Mann–Whitney U test. Fisher’s exact test
was used for assessment of distribution between groups.
For comparison of survival between groups, Kaplan
Meier plots were constructed and the log rank test used.
Multivariable linear regression analysis was used to
examine the relationship of apoptotic index (AI) to pro-
liferation and deletion status. Ki67 labelling index (LI)
was used as measure of the former, rather than Mcm2 LI,
as the latter also includes replication licensed but non-
proliferating cells. To model a diVerence in the slope of
the relationship between AI and Ki67 LI in the two sub-
groups, an interactive term between Ki67 LI and deletion
status was included [Model: AI = 0 +( 1 £ Ki67 LI) +
(2 £ deletion status) + (3 £ Ki67 LI £ deletion status)].
Results
Characteristics of the deletion sub-groups
FISH analysis for 1p and 19q deletion was successfully
performed in 54 out of 55 cases (Fig. 1). Cases were122 Acta Neuropathol (2007) 113:119–127
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assigned to the Del+ group if they had deletion of both
1p and 19q, or 1p alone. Cases were assigned to the
Del¡ group if they had no deletion or deletion of 19q
only. There were 34 Del+ cases and 20 Del¡ (Table 1).
The Del+ group had an older mean age than the Del¡
group (Table 2) (P = 0.002). There was no diVerence in
the distribution of histological grade between the two
groups (P =1 ) .
Survival analysis
Survival for the 47 cases included in the survival analy-
sis was taken from the date of the surgical resection.
The eight (recurrent) cases excluded from this analysis
were distributed evenly between Del+ and Del¡
groups. The Del+ group showed a trend to better sur-
vival (Fig. 2) but this did not reach signiWcance
(P = 0.092), probably due to the number of censored
cases. Further survival analysis to include multivariate
parameters was therefore not attempted.
Comparison of indices between cytogenetic subgroups
The labelling index for apoptotic bodies (AI), assessed
from H&E stained sections was used as a measure of
apoptosis. Higher levels of apoptosis were seen in the
Del+ group, carrying either deletions of 1p and 19q,
or 1p alone (P = 0.037) (Table 3, Fig. 3). To further
analyse the diVerence in apoptosis between the two
cytogenetic subgroups, we considered whether higher
levels of apoptosis in the Del+ group were a reXection
of higher cell turnover. However, there was no
diVerence in replication-licensed or proliferating cells
between the two subgroups as assessed by Mcm2
(P = 0.87) or Ki67 (P = 0.77), respectively. Inspection
of scatterplots of AI against Ki67 labelling index for
the two subgroups suggested that with increasing
Table 1 Results of FISH analysis
Group Deletion Number No. in 
Del group
% of 
cases
Del+ 1p 19q 34 34 63
1p 0
Del¡ None 17 20 37
19q 3
Fig. 1 Representative FISH 
images using the VYSIS dual 
colour probe sets; a relative 
loss of 1p (red) to 1q (green) 
with probable increase of 
chromosome number, 
b simple deletion of 1p (red), 
c relative loss of 19q (red) to 
19p (green) with probable 
increase of chromosome 
number, d simple deletion 
of 19q (red)
Table 2 Charateristics of cytogenetic sub-groups
Group Del+ Del¡
Mean age, SD 46.0, 11.5  33.1, 17.9
Grade II 16 9
Grade III 18 11
% of grade II 47.1 45.0Acta Neuropathol (2007) 113:119–127 123
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tumour proliferation, apoptosis shows a greater
increase in the Del+ subgroup (Fig. 4). Because this
suggested a steeper relationship of AI to proliferation
in the Del+ subgroup, multivariable regression analysis
was carried out with a model, incorporating Ki67 LI,
deletion status and a term for interaction between these
two variables as predictors of apoptosis index. This
gave an overall signiWcance of P = 0.002 for the model.
The interaction between Ki67 LI and deletion status
was signiWcant (P = 0.031) and AI rose more steeply
against Ki67 LI in the Del+ group (AI  0.58xKi67LI)
than in the Del¡ group (AI  0.13 Ki67 LI).
The diVerence between Mcm2 and Ki67 labelling
indices (Mcm2 ¡ Ki67 LI) was used as a measure of
the fraction of tumour cells that were licensed but not
proliferating. In general tumours showed a higher
labelling index for Mcm2 than Ki67, indicating the
presence of a population of licensed cells that are not
actively replicating. The Mcm2 ¡ Ki67 LI was higher
in grade III than in grade II tumours (P = 0.001, Fig. 5).
However, we demonstrated no diVerence in the pro-
portion of licensed, non-cycling cells by this method
between the two cytogenetic subgroups of oligoden-
drogliomas (P = 0.46). We also demonstrated no diVer-
ence in the geminin/Ki67 ratio (P =0 . 2 2 ) .
Discussion
The basis for the diVerence in clinical behaviour
between oligodendrogliomas with deletions of 1p and
19q (Del+) and those without (Del¡) remains unclear,
but its elucidation may yield important new avenues
for improved therapeutic approaches. In this study we
have investigated whether there are diVerences in para-
meters related to tumour cell proliferation and death in
these two cytogenetic subgroups of tumours.
The tumours were typed using FISH with probes to
1p and 19q. In our series, 63% of cases showed dele-
tions in 1p and 19q, or 1p alone, a similar proportion to
that reported in series of oligodendrogliomas in the lit-
erature where Wgures for combined loss from approxi-
mately 50 to 70% of cases have been described
(sometimes higher in classical appearing WHO grade II
tumours) [13, 19, 24, 25, 33]. Del+ and Del¡ had a simi-
lar distribution of histological grades whilst the older
average age in the Del+ group is also unlikely to be of
relevance to our Wndings as age is in general associated
with a worse clinical behaviour, and opposite to the
eVects here. A trend towards better overall survival in
Del+ cases in our series did not reach signiWcance, prob-
ably due to the number of total and censored cases.
Analysis of the FISH probes in this cohort of cases
revealed a pattern of multiple signals in some cases,
indicating that increased copy number of chromosomes 1
and 19 were present, but that there was still eVective loss
Fig. 2 Kaplan Meier survival curves for Del+ (solid line) and
Del¡ ( dashed line) oligodendroglioma subgroups. Censored
cases shown as cross marks
Table 3 Descriptive data for kinetic measures
AI apoptotic index, Mcm2 ¡ Ki67 Mcm2 minus Ki67 labelling in-
dex, Gem/Ki67 ratio of geminin to Ki67 indices, SD standard
deviation, IQR interquartile range
Subgroup Measure AI Mcm2 ¡ Ki67 Gem/Ki67
Del¡ Mean (SD) 0.72 (0.38) 8.31 (22.21) 0.39 (0.25)
Median (IQR) 0.60 (0.48) 6.65 (23.18) 0.38 (0.44)
Del+ Mean (SD) 1.10 (0.69) 12.51 (15.11) 0.29 (0.15)
Median (IQR) 0.95 (1.00) 7.15 (21.88) 0.26 (0.22)
Fig. 3 Boxplot showing apoptotic indices in Del¡ and Del+
subgroups124 Acta Neuropathol (2007) 113:119–127
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of heterozygosity of short arm chromosome 1 and
long arm chromosome 19. (Fig. 1) These cases were
interpreted Del+. One other subgroup was identiWed
in the cohort: three cases in which there was 19q dele-
tion present without concomitant 1p deletion. There
was no signiWcant association of these subgroups in
our series with an obvious pathological feature, but
more cases should be studied to determine any cli-
nico-pathological correlation. The multiple signal
cases, which would indicate complex aneuploid kary-
otypes, usually found in tumours with more malignant
status, may be of particular interest. One other group
has identiWed the single 19q deletion status cases and
have suggested that 19q deletion alone may also pre-
dict a favourable prognosis [22].
We have previously reported values for apoptosis,
Mcm2, Ki67 and geminin in this series of tumours
[45], but we now deWne indices and relate these to
cytogenetic subtype. We have investigated three
selected parameters that we hypothesise may aVect
survival and therapeutic response. Apoptosis is an
important process in tumour biology as defective
apoptosis induction may contribute to cancer devel-
opment and the susceptibility of tumour cells to apop-
tosis may aVect rate of growth. Apoptosis may be
induced by adjuvant therapies and is likely to become
an increasingly important molecular therapeutic tar-
get as speciWc pathways are deWned (reviewed in
[26]). Apoptosis is variable between tumour types
and a number of factors may contribute to apoptosis
induction in a tumour. The apoptotic index often
appears to be a function of the proliferation rate, with
higher levels in more rapidly cycling tumours. In oli-
godendrogliomas, we and others have previously
shown that apoptosis tends to increase with prolifera-
tion and with tumour grade [29, 43], though it has not
been shown to be an independent prognostic factor.
A similar relationship of apoptosis to histological
grade and proliferation has also been demonstrated
in the diVuse astrocytomas [8]. Although quantiWca-
tion of apoptosis, and so comparison between tumour
types and studies, is beset with methodological diY-
culties, there is evidence that oligodendrogliomas
show higher levels of apoptosis than other brain
tumours of comparative WHO grade [15, 28]. Altera-
tions in regulatory factors related to molecular
genetic changes are likely to be important in setting
the susceptibility to apoptosis in a given tumour type,
whilst other factors such as ischaemia and the inXu-
ence of tumoural inXammatory cells may also
contribute to apoptosis induction. Thus variation in
apoptosis is a candidate to explain diVerences in
clinical behaviour of tumour subtypes.
Fig. 4 Scatterplots of apopto-
sis index (AI) versus Ki67 
labelling index for Del¡ (left) 
and Del+ (right) cases
Fig. 5 Boxplot of Mcm2 minus Ki67 labelling index according to 
histological gradeActa Neuropathol (2007) 113:119–127 125
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In this series of oligodendrogliomas we have assessed
apoptosis using counts of apoptotic bodies. This method
has been used for other tumour types, including astro-
cytomas [8]. In a previous oligodendroglioma series we
showed that the apoptotic index correlates with an
assessment of apoptosis using the TUNEL method [43],
but it is a much simpler method. In addition, the
TUNEL technique can be capricious and lacks speciWc-
ity as it may detect DNA damage in cells from processes
other than apoptosis, including necrosis [12]. Immuno-
histochemical detection of caspase 3 has also been used
to detect apoptotic cells in histological sections [5]. We
have previously carried out caspase 3 immunohisto-
chemistry on this series [45], but this showed weaker
relationships to grade and proliferation than apoptotic
index using counts of apoptotic bodies. Therefore, for
this study, apoptotic index based on counts of apoptotic
bodies was selected a priori for analysis.
We have demonstrated that Del+ oligodendroglio-
mas show a higher apoptotic index than Del- tumours,
supporting the hypothesis that tumour cells from Del+
cases may have a greater susceptibility to undergo
apoptosis. We have not investigated the molecular
pathways that might lead to this diVerence. However, it
is not simply a reXection of increased cell turnover as
Del+ cases show no increase in either Mcm2 or Ki67
labelling indices compared to Del- cases (although a
diVerence in cell-cycle length is not formally excluded).
The greater rate of increase in apoptotic index against
Ki67 labelling index for Del+ than Del- tumours sug-
gests that oligodendrogliomas with 1p, 19q deletion
have a greater tendency to the induction of apoptosis
at higher rates of proliferation.
Immunohistochemical demonstration and quantiW-
cation of components of the DNA replication licensing
machinery have recently been used for prognostic [16,
30,  32,  44] and surveillance [37,  46,  47] studies in
human tumours. Theoretically demonstration of MCM
proteins may be considered superior to Ki67 as it iden-
tiWes not only cycling cells, but also those non-cycling
cells with proliferative potential [10, 38], and this supe-
riority is born out in many of these studies. Combined
assessment of these markers with other cell cycle
related markers may be used to obtain information on
the relative length of cell cycle phases in archival
biopsy material [9, 20, 31]. In this study, which adds to
these applications, we have used a variable generated
from the diVerence between the Mcm2 and Ki67 label-
ling indices (Mcm2-Ki67 LI) for each case to assess the
proportion of tumour cells that are licensed to replicate
but not actually in cycle. This index has been previ-
ously used in renal cell cancer, where it increases with
tumour grade [6]. We now also demonstrate that this
index increases with tumour grade in oligodendroglio-
mas, suggesting that the pool of cells that are licensed
but not proliferating is larger in more anaplastic
tumours, evidence for greater dysregulation of the ori-
gin licensing pathway with anaplasia. Such a licensed,
non-proliferating fraction might conceivably act as a
treatment-resistant population that could re-grow after
adjuvant therapy. There is increasing evidence for
tumour stem cells in brain tumours (reviewed in [11])
and it is intriguing to speculate whether a stem cell
population, responsible for perpetuating tumour
growth, might reside in this fraction. Its assay is there-
fore of potential interest and we hypothesised that the
size of this fraction might be greater in Del- tumours.
However, we did not demonstrate any diVerence in
Mcm2 ¡ Ki67 LI between Del+ and Del¡ tumours,
suggesting that this is not important in determining
their clinical diVerences.
We have previously shown that the ratio of geminin
to Ki67 labelling indices is increased in grade III versus
grade II oligodendrogliomas [45], implying a shortened
G1-phase in higher grade tumours (assuming that other
cell cycle phases are not substantially altered in dura-
tion). In this study, however, we have not demon-
strated evidence for a diVering G1-phase duration
between Del+ and Del¡ tumours.
Molecular diVerences between these two cytoge-
netic subtypes of oligodendroglioma are beginning to
be deWned, which will allow therapeutically relevant
molecular classiWcation [24]. Some of these genetic
diVerences likely relate to the regulation of apoptosis,
and may diVer in the two subgroups. This study has
shown that those oligodendrogliomas with 1p § 19q
deletions have higher apoptotic indices than those
without. DiVerences in cell death susceptibility may
aVect prognosis through a treatment independent
eVect on intrinsic growth rate. But apoptosis may also
be induced by adjuvant therapies, and amongst the
gliomas this may be particularly important for oligo-
dendroglial tumours [36]. This study does not allow
distinction between intrinsic growth rate and treatment
response contributions of apoptosis. It has also been
limited to histological methods and has not provided
functional data on susceptibility or deWned its molecu-
lar basis. However, the Wndings support the hypothesis
that diVerences in clinical outcomes between these
cytogenetic subgroups is related to diVering suscepti-
bility to apoptosis induction and suggest that detailed
comparative studies of apoptotic pathways in molecu-
lar subgroups of oligodendrogliomas are warranted.
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